Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: Use of propensity-score and instrumental variable methods to adjust for treatment-selection bias

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 5, 2012, Pages 470-484

  Suh, Hae Sun ^a,b   Hay, Joel W ^a   Johnson, Kathleen A ^a   Doctor, Jason N ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Yonsei University   (South Korea)

Author keywords

Cardiovascular disease; Comparative effectiveness research; Instrumental variable; Pharmacoepidemiology; Propensity score; Statin and fibrate; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; MEGLITINIDE; SULFONYLUREA;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; COMPARATIVE STUDY; FEMALE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FIBRIC ACIDS; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK FACTORS; SELECTION BIAS;

EID: 84859989387     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3261     Document Type: Article

References (34)

1. Berthold H, Gouni-Berthold I, Bohm M, Krone W, Bestehorn K. Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol 2009; 8: 25.
2. American Heart Association (AHA). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
3. Grant RW, Meigs JB. Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. Diabetes Care 2007; 30: 479-484.
4. Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 2005; 5: 379-387.
5. American Diabetes Association (ADA). Standards of medical care in diabetes--2006. Diabetes Care 2006; 29(Suppl 1): S4-S42.
6. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008; 5: 319-335.
7. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80: 608-613.
8. Farnier M, Roth E, Gil-Extremera B, et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007; 153: 335 e1-8.
9. Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis 1996; 7: 843-850.
10. Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000; 150: 429-436.
11. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
12. Nallamothu BK, Hayward RA, Bates ER. Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies. Circulation 2008; 118: 1294-1303.
13. Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 2007; 23: 553-563.
14. Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D, Cziraky M. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. Mayo Clin Proc 2008; 83: 1316-1325.
15. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8-27.
16. Hosmer DW, Lemeshow S. Applied Logistic Regression (2nd edn). John Wiley & Sons Inc.: New York, 2000; 373.
17. Allison PD. Logistic Regression using SAS Systems: Theory and Applications (2nd edn). SAS Institute, Inc.: Cary, NC, 2001.
18. Cameron AC, Trivedi PK. Microeconometrics: Methods and Applications (1st edn). Cambridge University Press: New York, 2005.
19. Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf 2010; 19: 537-554.
20. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006; 17: 268-275.
21. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables II: instrumental variable application--in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol 2009; 62: 1233-1241.
22. Greene WH. Econometric Analysis (5th edn). Prentice Hall: Upper Saddle River, New Jersey, 2003.
23. Lalani T, Cabell CH, Benjamin DK, et al. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation 2010; 121: 1005-1013.
24. Staiger D, Stock JH. Instrumental Variables Regression with Weak Instruments. Econometrica 1997; 65: 557-586.
25. Norton EC, Lindrooth RC, Ennett ST. Controlling for the endogeneity of peer substance use on adolescent alcohol and tobacco use. Health Econ 1998; 7: 439-453.
26. Imbens GW, Angrist JD. Identification and Estimation of Local Average Treatment Effects. Econometrica 1994; 62: 467-475.
27. Toth PP, Zarotsky V, Sullivan JM, Laitinen D. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. Curr Med Res Opin 2009; 25: 1355-1363.
28. Faul F, Erdfelder E, Lang AG, Buchner A. G*power 3: A flexible statistical power analysis program for the social, behanioral, and biomedical sciences. Behav Res Methods 2007; 39: 175-191.
29. ALLHAT-LLT Trial Investigators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.
30. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
31. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
32. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
33. Frances CD, Shlipak MG, Noguchi H, Heidenreich PA, McClellan M. Does physician specialty affect the survival of elderly patients with myocardial infarction? Health Serv Res 2000; 35: 1093-1116.
34. Greenfield S, Kaplan SH, Kahn R, Ninomiya J, Griffith JL. Profiling care provided by different groups of physicians: effects of patient case-mix (bias) and physician-level clustering on quality assessment results. Ann Intern Med 2002; 136: 111-121.